Beyond ACE inhibition: new developments in drug therapy for hypertension.
The growing list of vasoactive substances known to be involved in blood pressure control provides new targets for antihypertensive drugs. Currently under development are alternative strategies for blockade of the renin-angiotensin system (e.g., renin inhibition and angiotensin II receptor antagonism) that may have fewer side effects than angiotensin-converting-enzyme inhibition, and antagonists to other vasocontrictor peptides, such as endothelin and vasopressin. Novel strategies to enhance the effects of endogenous vasodilators, such as natriuretic peptides and nitric oxide, are also being explored.
Burrell
L M
LM
Department of Medicine, University of Melbourne, VIC.
Johnston
C I
CI
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015260:Neprilysin / Q000037:antagonists & inhibitors; D012084:Renin-Angiotensin System / Q000187:drug effects; D014667:Vasopressins / Q000037:antagonists & inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D014667:Vasopressins; D001120:Arginine; D015260:Neprilysin